bangsaitinib

Bangsaitinib (SYT-5108) is an orally bioavailable, potent, and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). Developed through a collaboration between Hangzhou Sanyintai Pharmaceutical Technology and Hangzhou Oz-Biomedical Technology, bangsaitinib is designed to treat various B-cell malignancies by disrupting the B-cell receptor (BCR) signaling pathway. BTK is a critical mediator in this pathway, and its inhibition leads to the suppression of proliferation and survival in malignant B cells. The drug is currently undergoing Phase 1/2 clinical evaluation in China for patients with relapsed or refractory B-cell lymphomas, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas.

Other names

邦赛替尼